Healthcare Industry News: uterine cancer
News Release - May 2, 2008
CytoCore Strengthens Sales and Marketing TeamEric Cohill Hired as SVP of Sales and Marketing
Company Hires Two Regional Sales Managers
CHICAGO--(HSMN NewsFeed)--CytoCore Inc. (OTCBB:CYOE ), the developer of cost-effective, highly accurate screening systems for early detection of gynecological cancers and sexually transmitted diseases, today announced the hiring of Eric Cohill as Senior Vice President of Sales and Marketing, Kenneth Ramsay as Regional Sales Manager Northeast and Cynthia Schwery as Regional Manager Mid-South. “As we commence the U.S. launch of SoftPAP, we are pleased to announce the addition of Eric, Ken and Cynthia to our Company,” said Robert McCullough, Jr., Chief Executive Officer of CytoCore. “Eric has a proven track record of building high performance sales teams and launching new technology to the marketplace. Ken and Cynthia both have strong medical device sales experience in their respective regions. The expertise and customer relationships of this team should provide us with a focused, rapid launch of SoftPAP.”
Eric Cohill has 23 years of successful sales and marketing experience working for several medical device companies at various stages of development. He was most recently Vice President of Sales at Viking Systems, where be built and managed their U.S. sales force. He spent thirteen years at United States Surgical, and nine years at start up or early stage medical companies including Cryogen and Laserscope, Inc. Eric will be responsible for building and managing a team of regional sales managers and independent distributors.
Kenneth Ramsay was most recently Regional Sales Manager, New England, for Medworx, an independent distributor of capital and disposable medical equipment. Ken has over 20 years of sales experience with Laserscope, Ethicon (a division of J&J) and Advanced Business Systems.
Cynthia Schwery was most recently at Viking Systems as National Manager of 3D Vision Services. Cynthia has over 10 years sales experience with Viking, Zonare and Sonosite. Cynthia began her career as an Echocardiographer.
“We are happy to have this team in place for the U.S. launch of our SoftPAP Collector at the American College of Obstetricians and Gynecologists Annual Meeting (ACOG) in New Orleans,” said Eric Cohill, SVP of Sales and Marketing. “We are very excited about the opportunity for SoftPAP. With its demonstrated accuracy and comfort, we believe this product will be very well received in the market.”
The SoftPAP® Cervical Cell Collector offers a quicker, more comprehensive way of collecting a specimen for Pap testing while minimizing the patient discomfort traditionally associated with the collection of this type of sample. SoftPAP® uses a patented single-use medical grade silicone rubber balloon to collect the sample. When the tip of this balloon is inserted into the endocervical canal and the balloon is inflated, it expands to contact the entire region from which a sample is to be obtained. Collecting the entire sample in a single step without the need to rotate or reposition the collector provides the physician with ease of use while reducing the possibility of sample collection errors. Unlike the rigid, hard edged cervical cell collection devices of the past, SoftPAP®’s soft, compliant balloon and controlled inflation promotes patient comfort by eliminating the need to scrape or abrade the cervix in order to obtain an adequate sample. The goal is to have a more comfortable procedure for the patient and ease of use for the physician. Additionally, the SoftPAP® was designed to collect cells with a “one touch” process, to reduce inadequate specimen collection. The theory is that the better specimen, the better chance of early detection of cervical dysplasia and related HPV.
About CytoCore Inc.
CytoCore develops cost-effective, highly accurate screening systems for early detection of gynecological cancers and sexually transmitted diseases. Designed for easy deployment at a laboratory or at the point-of-care, the CytoCore suite of sample collection technologies assists in the detection of cervical, endometrial, and other cancers, as well as the human Papilloma virus. The CytoCore Solutions™ System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the CytoCore Solutions™ System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.